Bromelains
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Bromelains is a protease indicated in the treatment of inflammation and for eschar removal.
- Generic Name
- Bromelains
- DrugBank Accession Number
- DB13281
- Background
Bromelain is a protease enzyme derived from the stems of pineapples that is composed of a mixture of different thiol endopeptidases and other components like phosphatase, glucosidase, peroxidase, cellulase, escharase, and several protease inhibitors 2. It works by selectively inhibiting the biosynthesis of proinflammatory prostaglandins 1 and also has analgesic properties, as well as anticancerous and pro-apoptotic effects. Bromelain holds potential therapeutic effect as a treatment of conditions including angina pectoris, bronchitis, sinusitis, surgical trauma, and osteoarthritis. It is considered as a safe food supplement.
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- Bromelain
- Bromelain juice
- Bromelain protease
- Bromelaina
- Bromelaines
- Bromelains
- Pineapple protease
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Associated Therapies
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Bromanase 1800 Tab 225mg Tablet 225 mg Oral Nf Formulas Inc. 1984-12-31 2000-06-21 Canada 
Bromelain 250 Capsule 250 mg Oral Thorne Research Inc. 1984-12-31 2005-08-26 Canada Bromelain 500 (300gdu/capsule) Capsule 500 mg Oral Quest Vitamins A Div Of Purity Life Health Products 1993-12-31 1999-08-30 Canada Bromelain 500mg Tablets Tablet 500 mg Oral Jamieson Laboratories Ltd 1996-09-10 2000-09-08 Canada Bromelain Pineapple Enzyme 50 Mg Nu Life Tablet 50 mg Oral Nu Life Nutrition Ltd. 1963-12-31 2000-03-03 Canada Bromelain Pwr Powder 20 mg / g Oral Everest Pharmaceuticals Ltd. 1979-12-31 1999-07-14 Canada Bromelain Tab 50mg Tablet 50 mg Oral Country Health Laboratories Ltd. 1982-12-31 2001-07-27 Canada Bromelain Tab 50mg Tablet 50 mg Oral Albi Imports Ltd. 1979-12-31 1996-09-09 Canada Bromelain Tablet 500mg Tablet 500 mg Oral Royal Bodycare Canada Inc. 1993-12-31 2001-08-07 Canada Gnc Natural Brand Tm Bromelain 100000gdu Tablet 50 mg Oral General Nutrition Canada Inc. 2002-10-20 2007-08-01 Canada - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Alka-pan Tablets Bromelains (50 mg) + Betaine hydrochloride (20 mg) + Ox bile extract (35 mg) + Pancrelipase (135 mg) + Papaya (125 mg) Tablet Oral Morter Healthsystem Not applicable Not applicable Canada Body Tropics Plus Tab Bromelains (50 mg) + Choline bitartrate (500 mg) + Inositol (250 mg) + Pyridoxine (25 mg) + Racemethionine (100 mg) Tablet Oral Pro Shop Inc. 1994-12-31 2008-08-02 Canada Bromelain and Papain Tab Bromelains (75 mg) + Papain (35 mg) Tablet Oral Vita Health Products Inc 1978-12-31 2002-07-31 Canada Chewable Enzymes Tablets Bromelains (15 mg) + Pancrelipase amylase (5 mg) + Papain (100 mg) Tablet Oral Gahler Enterprises Ltd. 1988-12-31 2002-07-17 Canada Cilobana Cpa Tab Bromelains (4 mg / tab) + Ascorbic acid (150 mg / tab) + Citrus bioflavonoids (75 mg / tab) + Hesperidin (75 mg / tab) + Vitamin A (10000 unit / tab) Tablet Oral Anabolic Laboratories Inc. 1968-12-31 1996-10-02 Canada KIMOSE Bromelains (50 mg) + Trypsin (1 mg) Tablet, sugar coated Oral บริษัท นิวไลฟ์ฟาร์ม่า จำกัด จำกัด 1998-01-27 2019-10-21 Thailand 
Pancreatin and Enzyme Formula - Tablet Bromelains (50 mg / tab) + Ox bile extract (5 mg / tab) + Pancrelipase (350 mg / tab) + Pancrelipase lipase (50 mg / tab) + Pepsin (100 mg / tab) Tablet Oral Health Wise Nutrition Inc. 1997-08-15 2000-07-29 Canada Papaya Bromelain Mycozyme Bromelains (45 mg) + Pancrelipase amylase (30 mg) + Papain (30 mg) Tablet Oral Alive Vitamins 1985-12-31 2002-07-12 Canada PLASIL®ENZIMATICO Bromelains (35000 U FIP) + Dehydrocholate sodium (20 mg) + Dimethicone (57.9 mg) + Metoclopramide hydrochloride (6.36 mg) + Pancrelipase (210 U FIP) Tablet, coated Oral LABORATORIOS BUSSIE S.A 2006-11-10 Not applicable Colombia 
Categories
- ATC Codes
- D03BA03 — Bromelains
- D03BA — Proteolytic enzymes
- D03B — ENZYMES
- D03 — PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS
- D — DERMATOLOGICALS
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- U182GP2CF3
- CAS number
- 9001-00-7
References
- General References
- Taussig SJ: The mechanism of the physiological action of bromelain. Med Hypotheses. 1980 Jan;6(1):99-104. [Article]
- Pavan R, Jain S, Shraddha, Kumar A: Properties and therapeutic application of bromelain: a review. Biotechnol Res Int. 2012;2012:976203. doi: 10.1155/2012/976203. Epub 2012 Dec 10. [Article]
- Brien S, Lewith G, Walker A, Hicks SM, Middleton D: Bromelain as a Treatment for Osteoarthritis: a Review of Clinical Studies. Evid Based Complement Alternat Med. 2004 Dec;1(3):251-257. Epub 2004 Oct 6. [Article]
- AIFA Product Information: NexoBrid (bromelain-enriched proteolytic enzymes) for topical use [Link]
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Supportive Care Dental Decay / Plaque, Dental 1 2 Unknown Status Treatment Malignancies 1 1, 2 Not Yet Recruiting Treatment Adenocarcinoma, Mucinous / Malignant Peritoneal Neoplasm / Mucinous Tumor / Pseudomyxoma Peritonei 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet, coated Oral Tablet, coated Oral 40 MG Tablet Oral Tablet Oral 225 mg Capsule Oral 250 mg Capsule Oral 500 mg Tablet Oral 50 mg Powder Oral 20 mg / g Tablet Oral 500 mg Tablet, sugar coated Oral Powder Cutaneous 2 G Powder Cutaneous 5 G Tablet, film coated Oral Tablet, coated Oral Tablet Oral 100 mg / tab Capsule Oral 500 mg / cap Tablet, delayed release Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on June 23, 2017 20:39 / Updated on October 22, 2021 23:18